Liu, Kathy Y;
Thambisetty, Madhav;
Howard, Robert;
(2022)
How can secondary dementia prevention trials of Alzheimer's disease be clinically meaningful?
Alzheimer's & Dementia
10.1002/alz.12788.
(In press).
Preview |
Text
Liu_Alzheimer s Dementia - 2022 - Liu - How can secondary dementia.pdf Download (256kB) | Preview |
Abstract
After clinical trial failures in symptomatic Alzheimer's disease (AD), our field has moved to earlier intervention in cognitively normal individuals with biomarker evidence of AD. This offers potential for dementia prevention, but mainly low and variable rates of progression to AD dementia reduce the usefulness of trials' data in decision making by potential prescribers. With results from several Phase 3 secondary prevention studies anticipated within the next few years and the Food and Drug Administration's recent endorsement of amyloid beta as a surrogate outcome biomarker for AD clinical trials, it is time to question the clinical significance of changes in biomarkers, adequacy of current trial durations, and criteria for treatment success if cognitively unimpaired patients and their doctors are to meaningfully evaluate the potential value of new agents. We argue for a change of direction toward trial designs that can unambiguously inform clinical decision making about dementia risk and progression.
| Type: | Article |
|---|---|
| Title: | How can secondary dementia prevention trials of Alzheimer's disease be clinically meaningful? |
| Location: | United States |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1002/alz.12788 |
| Publisher version: | https://doi.org/10.1002/alz.12788 |
| Language: | English |
| Additional information: | © 2022 The Authors. Alzheimer’s & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer’s Association. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
| UCL classification: | UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > Division of Psychiatry > Mental Health of Older People UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > Division of Psychiatry |
| URI: | https://discovery-pp.ucl.ac.uk/id/eprint/10156653 |
Archive Staff Only
 |
View Item |
